06.29.26 -- From Clinical To Market: Managing Pharma's Most Challenging Transition

Learn how to mitigate regulatory risk and improve trial diversity by reducing site burden and leveraging integrated technology to reach U.S. patients in their own communities.

AI-driven insights transform site selection and feasibility, enabling faster decisions and reducing risk. Predictive modeling and real-time data improve pre-award planning and trial outcomes.

Reveal how one family's race against time led to the creation of a groundbreaking gene therapy for their daughter, just 14 months after her ultra-rare disease diagnosis.

Get a clear, data-driven look at the biggest pressure points in cell therapy manufacturing. Explore the trends shaping today’s production challenges and where new opportunities are emerging.

Purpose-built early-phase oncology sites can enroll patients within 7–10 days post-activation while maintaining quality and diversity; academic centers often lag due to complexity and saturation.

A former manufacturing site is reborn as a training hub that combines industry-shaped labs, employer-driven curriculum, and flexible programs to prepare a workforce ready for evolving demands.

Discover some of the questions you can consider to avoid hidden costs when managing your supply chain and mitigating risk for materials used directly in bioproduction.

Understand how lyophilization revolutionizes biologic drug manufacturing and ensures potent, stable treatments for complex diseases.

Computational Fluid Dynamics simulation is essential for robust biologics tech transfer. See how this predictive tool optimizes critical scale-up processes, reducing risk and expediting time to market.